For laboratory research use only.) Triple receptor agonism (GLP-1R + GIPR + GCGR) synergistic receptor activation studied in preclinical models Phase 2 clinical trial data examining body weight as a primary endpoint at 48 weeks (pubmed.ncbi.nlm.nih.gov) Preclinical and observational data examining glycemic markers and hepatic lipid content in research models (pmc.ncbi.nlm.nih.gov) Glucagon receptor activation pathways studied in relation to energy expenditure and lipid oxidation in animal models Triglyceride and cardiometabolic marker data examined in controlled research settings Applicable across metabolic dysfunction, hepatic steatosis, glycemic regulation, and cardiovascular outcome research models Why Researchers Choose GLP-3R from Nationwide Peptides Sequence verified against published literature (including lipidation profile) High purity with receptor-binding fidelity confirmed by COA Transparent analytical data (HPLC 98%, triple-receptor activity confirmed) Suitable for academic, pharmaceutical, and metabolic-disease laboratory research Competitive research pricing with bulk options This product is for laboratory research use only
For the treatment of cerebrocortical necrosis in Cattle and Sheep, the treatment of bracken poisoning in Horses and for the treatment of Vitamin B deficiencies in Horses, Cattle and Sheep
+29% firmness
Therefore, there are limited clinical trial data with semaglutide use in pregnant women. Animal studies have suggested semaglutide can cause foetal abnormalities
We compare metabolomic, transcriptomic, and genetic pathway differences among three sterile mutants: germline-less glp-1 , feminized fem-3 , and masculinized mog-3
If you have allergies or sensitivities to common preservatives like methylparaben, work with your PlexusDx provider to request a customized formulation
